New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies

Kieron Dunleavy, Richard L. Piekarz, Jasmine Zain, John Edward Janik, Wyndham H. Wilson, Owen A. O'Connor, Susan E. Bates

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Peripheral T-cell lymphomas (PTCL) constitute a group of heterogeneous diseases that are uncommon, representing, in Western countries, only approximately 10% of all non-Hodgkin lymphomas. They are typically associated with a poor prognosis compared with their B-cell counterparts and are much less well understood with respect to tumor biology, owing to their rarity and biologic heterogeneity, and to the fact that characteristic cytogenetic abnormalities are few compared with B-cell lymphomas. Although the outcome for patients with anaplastic large cell lymphoma (ALCL), particularly anaplastic lymphoma kinase (ALK)-positive ALCL, is good, other types of PTCLs are associated with a poor prognosis, even with aggressive anthracycline-based chemotherapy. In this respect, there is a need for new approaches in these diseases, and this review focuses on and explores recent experience with novel therapies in PTCL.

Original languageEnglish (US)
Pages (from-to)5608-5617
Number of pages10
JournalClinical Cancer Research
Volume16
Issue number23
DOIs
StatePublished - Dec 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dunleavy, K., Piekarz, R. L., Zain, J., Janik, J. E., Wilson, W. H., O'Connor, O. A., & Bates, S. E. (2010). New strategies in peripheral T-cell lymphoma: Understanding tumor biology and developing novel therapies. Clinical Cancer Research, 16(23), 5608-5617. https://doi.org/10.1158/1078-0432.CCR-09-1995